Halozyme Therapeutics | HALO - Current Liabilities

Stock Price
76.76
Daily Change
2.31 3.10%
Monthly
7.81%
Yearly
35.21%
Q1 Forecast
69.50

Halozyme Therapeutics reported $837.23M in Current Liabilities for its fiscal quarter ending in September of 2025.





Current Liabilities Change Date
Acadia Pharmaceuticals USD 356.58M 26.56M Sep/2025
Agios Pharmaceuticals USD 74.76M 4.35M Sep/2025
Alnylam Pharmaceuticals USD 1.56B 254.63M Sep/2025
Amarin USD 182.23M 3.71M Sep/2025
Amgen USD 21.79B 1.32B Sep/2025
Baxter International USD 3.78B 836M Sep/2025
Cytokinetics USD 142.14M 11.08M Sep/2025
DBV Technologies USD 49.48M 60K Sep/2025
Eli Lilly USD 40.14B 1.12B Sep/2025
Halozyme Therapeutics USD 837.23M 702.95M Sep/2025
Ionis Pharmaceuticals USD 903.46M 6.22M Sep/2025
MannKind USD 109.13M 2.7M Sep/2025
Pfizer USD 36.6B 1.13B Sep/2025
United Therapeutics USD 546.3M 19.2M Sep/2025